StemCell InstituteJP:7096

Market cap
¥16.7B
P/E ratio
53.6x
Mar 31,
2019
Mar 31,
2020
Mar 31,
2021
Mar 31,
2022
Mar 31,
2023
Mar 31,
2024
Profit (loss) before income taxes21538391213279441
Depreciation35323397105121
Head office relocation expenses-OpeCF----21-
Increase (decrease) in allowance for doubtful accounts-00-1120
Increase (decrease) in provision for bonuses3165-162
Increase (decrease) in provision for retirement benefits for directors (and other officers)-333127
Interest and dividend income-0-0-0-1-2-4
Loss on retirement of non-current assets1-1--0
Loss (gain) on sale of investment securities-0----22
Decrease (increase) in trade receivables-104-101-1-314-546-447
Decrease (increase) in inventories-2-3-16-81-3
Increase (decrease) in trade payables604905
Increase (decrease) in accounts payable - other-16-1178610
Increase (decrease) in accrued consumption taxes1526-4757-174
Increase (decrease) in advances received268423337330350325
Other, net5-7-64-104
Subtotal426762358461207442
Interest and dividends received000023
Income taxes paid-35-94-124-14-109-111
Net cash provided by (used in) operating activities391668239469100335
Payments into time deposits-751-751-751---500
Proceeds from withdrawal of time deposits6007517517501-
Purchase of investment securities---105--143-200
Proceeds from sale of investment securities-----72
Purchase of property, plant and equipment-29-59-401-181-56-183
Purchase of intangible assets-0-6-2-23-4-18
Payments of leasehold and guarantee deposits-0-40-9-9-48-7
Other, net-3-3-31-3524
Net cash provided by (used in) investing activities-184-108-520404-285-812
Repayments of lease liabilities-----1-1
Purchase of treasury shares-----0-
Net cash provided by (used in) financing activities---644-1-1
Net increase (decrease) in cash and cash equivalents207560-2811,518-186-478